MED — Medifast Cashflow Statement
0.000.00%
Last trade - 00:00- $145.52m
- -$19.07m
- $602.46m
- 98
- 57
- 65
- 86
Annual cashflow statement for Medifast, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 103 | 164 | 144 | 99.4 | 2.09 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.88 | 15.1 | 19.3 | 13.6 | 26.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 26.6 | -87.6 | 21.7 | 20.3 | -9.74 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 145 | 94.5 | 195 | 148 | 24.5 |
| Capital Expenditures | -5.89 | -34.2 | -16.7 | -6.48 | -7.45 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 4.61 | 5.14 | 5.27 | -54.6 | -19.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.28 | -29.1 | -11.4 | -61 | -26.5 |
| Financing Cash Flow Items | -0.551 | -6.09 | -1.52 | -3.36 | -0.836 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -57.1 | -125 | -200 | -79.8 | -1.51 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 86.7 | -59.5 | -16.5 | 6.75 | -3.51 |